THOUSAND OAKS, Calif., July 16, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of BLINCYTO® (blinatumomab) in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL). The investigational study showed blinatumomab monotherapy induced a complete remission […]

Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round. The oversubscribed round includes new investors, Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and […]

Five Prime Therapeutics Establishes Strategic Research Collaboration and License Agreement With Inhibrx for Novel GITR Antibodies Inhibrx’s technology may offer best-in-class approach for agonist antibodies New program further expands Five Prime’s immuno-oncology pipeline and potential for combination therapies SOUTH SAN FRANCISCO, Calif., and LA JOLLA, Calif., July 15, 2015 (GLOBE NEWSWIRE) — Five Prime Therapeutics, […]

July 16, 2015By Mark Terry, BioSpace.com Breaking News Staff Rumors are flying that three companies specializing in CAR-T cancer therapies may be attractive targets for acquisition. The big three in this area are Juno Therapeutics (JUNO), Kite Pharma, Inc. (KITE), and bluebird bio (BLUE). A potential fourth is Cellectis S/A. CAR-T therapy involves removing particular […]

Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Alprolix (rFIXFc) for the territory composed of Europe, North Africa, Russia and certain Middle Eastern markets. Alprolix is a recombinant factor IX Fc fusion protein product candidate […]

July 14, 2015By Alex Keown, BioSpace.com Breaking News Staff SUMMIT, N.J. – Celgene Corporation (CELG) has struck again, acquiring Receptos, Inc. (RCPT) for $7.2 billion to enhance the company’s inflammation and immunology portfolio. The acquisition was announced Tuesday afternoon. The acquisition brings some key drugs into Celgene’s pipeline, including Ozanimod, an oral once-daily, selective sphingosine […]

July 15, 2015By Alex Keown, BioSpace.com Breaking News Staff CAMBRIDGE, Mass. –All eyes will be focused on Biogen, Inc. next week as the pharmaceutical company is expected to reveal the latest data in its Alzheimer’s trial – data that could lead to either a breakthrough or another roadblock for Alzheimer’s care. There is currently no […]

Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. Celgene, whose shares rose nearly 6 percent in extended trading to $130.15, said it would pay $232 […]

Drug developer Zogenix Inc said it would delay by three months the start of late-stage trials for its drug to treat a rare form of epilepsy in children. Zogenix decided to delay the trials for ZX008 after the U.S. Food and Drug Administration asked for more patients to be enrolled in the studies. Zogenix plans […]

Paul Allen, philanthropist and co-founder of Microsoft, has devoted many millions of dollars to unlocking the mysteries of the brain, and today he’s taking on a new challenge: Alzheimer’s disease. The Paul G. Allen Family Foundation, launched by the tech mogul and his sister, Jody Lynn, in 1988, has awarded $7 million in grants to […]